The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 03, 2018
Filed:
Jan. 09, 2015
Applicant:
Retinal Therapies Llc, Coronado, CA (US);
Inventor:
Gerald Horn, Deerfield, IL (US);
Assignee:
Retinal Therapies, LLC, Coronado, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/10 (2017.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01); A61K 47/38 (2006.01); A61K 31/47 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/53 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 9/107 (2006.01);
U.S. Cl.
CPC ...
A61K 47/20 (2013.01); A61K 9/0048 (2013.01); A61K 9/107 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/53 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01);
Abstract
The invention provides compositions and methods for the treatment of intraocular neovascularization and/or leakage including wet age-related macular degeneration. The compositions preferably use tyrosine kinase inhibitors with an IC50 for VEGFR2 of 20 nanomolars or less and an IC50 for c-MET of 20 nanomolars or less.